BINVS Stock Overview
A clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
BioInvent International AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 34.75 |
| 52 Week High | SEK 39.45 |
| 52 Week Low | SEK 34.70 |
| Beta | 0.30 |
| 1 Month Change | 0% |
| 3 Month Change | -3.87% |
| 1 Year Change | n/a |
| 3 Year Change | -4.40% |
| 5 Year Change | -31.86% |
| Change since IPO | -43.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| BINVS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.4% | 1.2% |
| 1Y | n/a | -23.8% | 4.3% |
Return vs Industry: Insufficient data to determine how BINVS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how BINVS performed against the UK Market.
Price Volatility
| BINVS volatility | |
|---|---|
| BINVS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.5% |
Stable Share Price: BINVS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BINVS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 93 | Martin Welschof | www.bioinvent.com |
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma.
BioInvent International AB (publ) Fundamentals Summary
| BINVS fundamental statistics | |
|---|---|
| Market cap | SEK 2.07b |
| Earnings (TTM) | -SEK 42.93m |
| Revenue (TTM) | SEK 310.39m |
6.7x
P/S Ratio-48.3x
P/E RatioIs BINVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BINVS income statement (TTM) | |
|---|---|
| Revenue | SEK 310.39m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 310.39m |
| Other Expenses | SEK 353.32m |
| Earnings | -SEK 42.93m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 22, 2023
| Earnings per share (EPS) | -0.65 |
| Gross Margin | 100.00% |
| Net Profit Margin | -13.83% |
| Debt/Equity Ratio | 0% |
How did BINVS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/02/08 11:30 |
| End of Day Share Price | 2022/11/11 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioInvent International AB (publ) is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Morten Larsen | ABG Sundal Collier |
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Mattias Häggblom | Danske Bank |